Advanced searches left 3/3

Carboplatin Trial - Crossref

Summarized by Plex Scholar
Last Updated: 03 August 2022

* If you want to update the article please login/register

A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical

Abstract Background: Cervical cancer is the fourth most common health condition in women, and it is affecting female reproductive tract health. Chemotherapy can be used for neoadjuvant therapy for patients with high risk factors, so as to reduce the focus, sensibilize radiotherapy, and minimize recurrence, Chemotherapy can be used for neoadjuvant therapy of locally developed cervical cancer and postoperative adjuvant therapy for patients with high-risk factors. As 2 O 3 alone or in combination with platinum drugs have demonstrated excellent success in a variety of tumors both in vivo and in vitro. Moreover, our study group has shown that the use of As 2 O 3 combined with platinum drugs in cervical cancer treatment is not inferior to the conventional first-line regimen at the cellular and animal levels, and that paclitaxel is more costly than As 2 O 3. Hence, we aim to assess the clinical effectiveness and safety of neoadjuvant chemotherapy with As 2 O 3 and carboplatin in locally advanced cervical cancer. Eligible patients will be given either 2 cycles of paclitaxel and carboplatin, as 2 O 3 and carboplatin every three weeks or as a 3 week. Patients with disease-controlled or disease progression at these time points will be able to receive concurrent chemotherapy and radiation therapies directly, while responders will be treated with PiverRutledge grade III radical hysterectomy and bilateral pelvic lymphadenectomy. Discussion This is the first single-center, prospective, two-arm construction, open-label controlled trial that will determine the clinical relevance and safety of neoadjuvant chemotherapy with As 2 O 3 and carboplatin in locally advanced cervical cancer.

Source link: https://doi.org/10.1186/s13063-022-06489-1


Low Dose Olanzapine in the Prevention Carboplatin Induced Nausea and Vomiting: a Prospective Randomized Controlled Trial

Methods Both patients with malignant tumors receiving carboplatina u22655aff06chemotherapy were randomly divided into two groups: a triplet regiment group and a control group. Patients in the olanzapine group received 5 mg olanzapine, 5-HT 3 RA, and dexamethasone triplet antiemetic therapy, while those in the normal group received 5-HT 3 RA and DXM. Conclusion: The 3mg olanzapine-based triplet antiemetic regimen is safe and effective in the prevention of carboplatin-induced nausea and vomiting, particularly in the control of the nausea.

Source link: https://doi.org/10.21203/rs.3.rs-892475/v1


Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non–small cell lung cancer with untreated brain metastases.

9010 Background: In the ATEZO-BRAIN study, Atezolizumab plus chemotherapy was safe and yielded promising clinical results as frontline therapy for patients with advanced NSCLC with untreated brain metastases. Compared to PD-L1 negative pts, PD-L1 positive pts was longer than PD-L1 negative pts than PD-L1 negative pts, but no differences were statistically significant because of limited statistical resources. No significant differences in OS were found between patients receiving or not baseline DXM therapy. Conclusions: In this updated review, atezolizumab plus carboplatin and pexed yields a promising 2-year OS rate and intracranial response rate in patients with untreated BM from NSCLC, despite corticosteroids treatment at baseline and PD-L1 expression.

Source link: https://doi.org/10.1200/jco.2022.40.16_suppl.9010


Abstract S1-06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66)

In the neoadjuvant Geparsixto study, we have recently reported a dramatically elevated pCR rate in triple-negative breast cancer with the addition of carboplatin to a non-pegylated liposomal doxorubicin/taxane mixture. Methods: Geparsixto investigates the effect of adding carboplatin to MC for the care of patients with HER2+ve and triple-negative primary BCs. All HER2+ve patients received trastuzumab and lapatinib, while all TN patients received bevacizumab. As previously reported, we used the terms stromal lymphocytes and lymphocyte-predominant breast cancer. Both therapeutic groups had the same results: In patients treated with MC, the incidence of the lymphocytic infiltrate was moderately elevated in LPBC. In comparison to 38. 1% for non-LPBC tumors, the pCR rate in patients who received additional carboplatin to MC was up 75% in LPBC tumors. The pCR rates in TNBC patients treated with MC+carboplatin were 72% for LPBC, compared to 52% for non-LPBC. The pCR rates in Her2+ve patients treated with MC+carboplatin were 71% for LPBC and 21. 9 percent for non-LPBC. Mutations in exons 5-8 of the p53 gene were not associated with changes in pCR count, neither in the overall population nor in the two treatment arms. The incorporation of immunological biomarkers could help identify patients with the highest benefit from carboplatin therapy, particularly in relation to the MC+carboplatin combination's relevant toxicity.

Source link: https://doi.org/10.1158/0008-5472.sabcs13-s1-06


Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL

Background: Abstract Background: I-SPY 2 is a multicenter, phase 2 screening trial utilizing adaptive randomization within biomarker subtypes to determine a range of novel agents/combinations when added to standard neoadjuvant therapy vs. T/AC for women with high-risk stage II/III breast cancer. One of 7 experimental trials evaluated in the trial to date, we announce final efficacy results of the oral PARP inhibitor veliparib in combination with carboplatin. In a longitudinal research scheme to increase adaptive randomization's effectiveness, MRI scans were used in a longitudinal statistical framework to increase adaptive randomization's reliability. We estimate pCR rates for the three key parameters in the Bayesian probability intervals for V+carbo and simultaneously randomized controls for these three key metrics. For each signature, we have probabilities of superiority for V+carbo over control and Bayesian predictive probabilities of success in a randomized comparison between V+carbo and control in a neoadjuvant Phase 3 trial equally divided between V+carbo and control. Results: When V+carbo achieved the 85% predictive probability criterion in HR-/HER2- and all HER2-, this program was discontinued, as accrual to V+carbo was suspended. Both patients who were not included in the table were not enrolled in the study but two patients who were assigned to V+carbo during hospitalization refused to participate in the procedure and were not included in the table. 99%9 percent Conclusion: Adaptive randomization found a biomarker signature for V+Carbo at a rate of 56%HR+/HER2-52 percent 94 percent 94%24% 92 percent. The I-SPY 2 standing trial system effectively screens agents/combinations in biomarker-defined patient subsets, with future agents/combinations notified as available.

Source link: https://doi.org/10.1158/0008-5472.sabcs13-s5-02


Abstract S1-02: Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07)

Abstract BACKGROUND: The BCIRG006 research found similar efficacy and superior safety of adjuvant docetaxel, carboplatin, and trastuzumab for an anthracycline treatment in HER2+ BC. In HER2+ BC, this research examines the neoadjuvant TC plus H and/or Ty's medical and molecular effects. METHODS: This is an open-label, randomized phase II research in which pts from stage I-III, operable BC, and Arm 3-TCHTy were assigned to 1 of 3 arms: Arm 1-TCH, Arm 2-TCTy, and Arm 3-TCHTy. The first 20 pts were TCHTy to determine the safety of TCHTy. Pts were treated to a run-in cycle of Ty and/or H, followed by six cycles of q3-wkly TC plus H and/or Ty. Complete records were available for 106 pts: 32 in Arm 1, 27 in Arm 2 and 47 in Arm 3, as of May 2013, as of May 2013. Of these, 16 patients came off study tx prior to surgery but are included in the ITT studies. In 43 pts, there were both negative and/or PR positive, and they were ER and/or PR positive in 63 cases. At presentation, 5 pts had clinical stage I, 71 stage II, and 30 stage III BC. Arms 1 and 2 were both lower in Arm 2 than in Arm 3, with 53% HR+ versus 68% HR-for Arm 3, and 33% HR+ vs 68% HR-for Arm 3.

Source link: https://doi.org/10.1158/0008-5472.sabcs13-s1-02


Abstract P4-12-17: Pathological responses and heart safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy in clinical stage II-III, HER2-positive breast cancer patients: A phase 2, open-label, multicentre, randomised trial

Abstract Purpose: Neoadjuvant chemotherapy can provide early indications of treatment response, according to a review of the treatment regimen. For the PEH group, Trastuzumab and Pacitaxel weekly combined with Carbopatin weekly; Epithel for PCH group or Epitoxin every three weeks. 50 patients were randomly selected to receive PCH treatment and 50 were selected to receive the PEH regimen by Aug. 16, 2012; 50 were not allocated to receive the PEH regimen and 50 were randomly assigned to the PEH regimen and 50 were lucky to receive the PEH therapy. 49 people registered to TNM stage II, while 51 others were dedicated to TNM stage III, 51 of whom were TNM stage II. Compared to the PCH regimen, the PEH regimen had a significant rise in pCR in the luminal-B subgroup but not in the ERBB2+ subgroup. At baseline, Median LVEF was 66. 6 percent, with no difference between the PCH and PEH groups. There was no difference in LVEF after two cycles in 82 patients, the median LVEF was 64. 7%, no difference in LVEF. The median LVEF was 66. 6 percent in 80 patients after four cycles, but no difference was found between the PCH and PEH groups. After two cycles, 5 patients in the PCH group and 3 patients in the PEH group all had LVEF decreases of more than 10%, of which 5 patients in the PCH group and 3 patients in the PEH group experienced LVEF decreases of over 10%, of which 5 patients in the PCH group and 3 patients in the PEH group. Following more than four cycles, 3 patients in the PCH group, and 1 patient in the PEH group had LVEF drops of over 10. 0% compared to baseline. Conclusion: Both PCH and PEH regimens as neoadjuvant chemotherapy have the same pCR rate for breast cancer patients with HER2-overexpression. PEH is safe and is not likely to raise the incidence of acute cardiac events in comparison to PCH.

Source link: https://doi.org/10.1158/0008-5472.sabcs13-p4-12-17


Abstract P3-14-14: Neoadjuvant phase II trial with carboplatin and eribulin in triple negative breast cancer patients

Abstract: Several neoadjuvant trials have been conducted aimed at treating triple negative breast cancer patients with platinum agents with pathologic complete response rates ranging from 16%-32%. The combination of eribulin mesylate and carboplatin was well tolerated and demonstrated activity in advanced solid tumors, according to a new phase I trial. In patients with TNBC, we suggested a neoadjuvant phase II trial, utilizing carboplatin and eribulin. On days 1 and 8 and 8 patients were treated at 1. 4 mg/m2 followed by carboplatin AUC = 6 on day 1 every 21 days for a total of four cycles. We wanted to find the pCR in TNBC patients treated with the combination of carboplatin and eribulin as the primary endpoint. The trial was temporarily suspended after the 10th patient; toxicity was tested for the first ten patients to see whether eribulin at 1. 4 mg/m2 or a dose cut to 1. 1 mg/m2 will be required for the remaining patients. Of the first 10 patients, only 2 of 10 were diagnosed with grade 3 or 4 neutropenia, and no one of ten patients had experienced grade 3 or 4 peripheral neuropathy. The trial was continued for the remaining 20 patients with eribulin dosed at 1. 4 mg/m2 and carboplatin AUC = 6. For grade 3 or 4 neutropenia, 8 of the 24 patients who have completed therapy required a dose reduction in eribulin. Conclusion: In patients with TNBC, the combination of carboplatin and eribulin in the neoadjuvant setting appears to be safe and effective.

Source link: https://doi.org/10.1158/0008-5472.sabcs13-p3-14-14


Abstract P3-14-07: Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer - A phase II clinical trial

Abstract Background: Combination anthrathyclin-taxane regimens are the most widely used neoadjuvant chemotherapy for triple negative breast cancer with objective response rates of about 80% but poor pathological complete response rates and survival are typical. Several small clinical studies have shown that cisplatin- or carboplatin-containing chemotherapy may have higher pCR rates. However, no studies have been conducted into the safety of platinum combination chemotherapy with a traditional anthrathyclin-taxane regimen. In the neoadjuvant setting, this research was conducted to determine the correct option for TNBC, finding carboplatin plus paclitaxel with epiticin plus paclitaxel to determine the correct option for TNBC. Patients with ER/PR/Her-2 negative breast cancer were enrolled in core needle biopsy immunohistochemistry. The percentage of patients with basal-like subtype in the two arms was 97. 3 percent vs. 91. 67. The PC and EP arm's ORR was similar, but the PC arm's pCR was much higher than the EP arm's, but the PC arm's pCR rate was much higher than the EP arm. Eighty-eight percent of deaths occurred in the first three years after diagnosis. Compared to non-pCR patients, pCR patients had significantly improved 4-year RFS and 4-year OS in comparison to non-pCR patients. Conclusion The PC regimen, in comparison to the most widely used EP chemotherapy, could greatly raise TNBC's pCR rate, according to TNBC, and the 4-year RFS showed a trend toward decline. Overall, the pCR patients'u2019 prognosis was much better than non-pCR patients. TNBC neoadjuvant therapy may be the most appropriate option for TNBC neoadjuvant therapy.

Source link: https://doi.org/10.1158/0008-5472.sabcs13-p3-14-07


Abstract PD09-06: Two phase I trials exploring different dosing schedules of carboplatin (C), paclitaxel (P), and the poly-ADP-ribose polymerase (PARP) inhibitor, veliparib (ABT-888) (V) with activity in triple negative breast cancer (TNBC)

Abstract Background: The histopathologic and molecular similarities between TNBC and BRCA-1 mutation-related breast cancer provide support for the use of PARP inhibitors in treating sporadic TNBC. Advance breast cancer drugs, C and P, are well-established drugs in the treatment of advanced breast cancer. Two independent phase I trials tested the combination of V with C and P dosed weekly and every three weeks in order to determine the appropriate phase II dose of V in combination with C and P. Methods: Both phase I trials were a standard 3+3 dose escalation strategy of C, P, and V, which was open to patients with advanced solid tumors and TNBC-enriched for pts with TNBC. C was delivered on the third day of every 21 days at an AUC of 6, P was administered on day 3 of 1,200 mg/m2 to a dose of 120 mg/m2 above nine dose levels in the q3wk trial. Responses are evaluable for ten breast cancer pts. An additional 12 pts with TNBC will be accrued to the q1wk trial with pre- and post-treatment biopsies to further investigate the root of sensitivity and response with respect to DNA repair pathways.

Source link: https://doi.org/10.1158/0008-5472.sabcs12-pd09-06

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions